Patents by Inventor Armon R. Sharei
Armon R. Sharei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12201652Abstract: The present invention provides methods for inducing tolerance and/or suppressing an immune response to an antigen by passing a cell suspension containing an anucleate cell through a constriction, wherein the constriction deforms the cell thereby causing a perturbation of the cell such that an antigen and/or tolerogenic factor enters the cell. In some embodiments, the anucleate cell is delivered to an individual and the antigen is delivered to and processed in a tolerogenic environment to induce tolerance and/or suppress an immune response to the antigen.Type: GrantFiled: May 3, 2017Date of Patent: January 21, 2025Assignee: Stemcell Technologies Canada Inc.Inventors: Jonathan B. Gilbert, Bu Wang, Scott Loughhead, Howard Bernstein, Armon R. Sharei, Finola Moore
-
Patent number: 12150982Abstract: The present application provides formulations of modified peripheral blood mononuclear cells (PBMCs), wherein the formulation comprises: PBMCs comprising at least one antigen (e.g., a human papillomavirus (HPV) antigen) and a cryopreservation medium. In some embodiments, the PBMCs are conditioned by incubating the PBMC in the presence of an adjuvant.Type: GrantFiled: December 28, 2021Date of Patent: November 26, 2024Assignee: STEMCELL TECHNOLOGIES CANADA INC.Inventors: Howard Bernstein, Scott Loughhead, Matthew Booty, Kelan Hlavaty, Tarek Abdeljawad, Maisam Dadgar, Jason Murray, David Chirgwin, Harry An, Armon R. Sharei
-
Publication number: 20240376415Abstract: A microfluidic chip for causing the delivery of a payload to a cell comprises a plurality of constrictions configured to allow a cell suspension to flow through one or more of the plurality of constrictions from a first fluid flow region to a second fluid flow region within the microfluidic chip, wherein a cross-sectional width of each of the plurality of constrictions is less than a diameter of cells in the cell suspension, such that membranes of the cells are perturbed when passing through the constrictions such that a payload is able to pass through the perturbed cell membranes, and wherein a quotient of a cross-sectional area over a cross-sectional perimeter of each of the plurality of constrictions is greater than greater than or equal to 0.5 ?m.Type: ApplicationFiled: May 16, 2024Publication date: November 14, 2024Inventors: Maisam DADGAR, Jacquelyn L. Sikora HANSON, Armon R. SHAREI
-
Patent number: 12130281Abstract: Gene editing can be performed by introducing gene-editing components into a cell by mechanical cell disruption. Related apparatus, systems, techniques, and articles are also described.Type: GrantFiled: August 17, 2021Date of Patent: October 29, 2024Assignees: Massachusetts Institute of Technology, President and Fellows of Harvard CollegeInventors: Armon R. Sharei, Marc Lajoie, Klavs F. Jensen, Robert S. Langer
-
Publication number: 20240228956Abstract: The present application provides peripheral blood mononuclear cells comprising an antigen, methods of manufacturing such PBMCs, and methods of using such PBMCs, such as for modulating an immune response in an individual. In some embodiments, the PBMCs are conditioned by incubating the PBMC in the presence of an adjuvant.Type: ApplicationFiled: May 17, 2023Publication date: July 11, 2024Applicant: SQZ Biotechnologies CompanyInventors: Armon R. SHAREI, Howard BERNSTEIN, Scott LOUGHHEAD, Matthew BOOTY, Katarina BLAGOVIC, Kelan HLAVATY, Defne YARAR, Emrah Ilker OZAY, Carolyne Kelly SMITH
-
Patent number: 12018240Abstract: A microfluidic chip for causing the delivery of a payload to a cell comprises a plurality of constrictions configured to allow a cell suspension to flow through one or more of the plurality of constrictions from a first fluid flow region to a second fluid flow region within the microfluidic chip, wherein a cross-sectional width of each of the plurality of constrictions is less than a diameter of cells in the cell suspension, such that membranes of the cells are perturbed when passing through the constrictions such that a payload is able to pass through the perturbed cell membranes, and wherein a quotient of a cross-sectional area over a cross-sectional perimeter of each of the plurality of constrictions is greater than greater than or equal to 0.5 ?m.Type: GrantFiled: December 27, 2021Date of Patent: June 25, 2024Assignee: STEMCELL TECHNOLOGIES CANADA INC.Inventors: Maisam Dadgar, Jacquelyn L. Sikora Hanson, Armon R. Sharei
-
Publication number: 20240132839Abstract: The present application provides peripheral blood mononuclear cells comprising an antigen, methods of manufacturing such PBMCs, and methods of using such PBMCs, such as for modulating an immune response in an individual. In some embodiments, the PBMCs are conditioned by incubating the PBMC in the presence of an adjuvant.Type: ApplicationFiled: May 16, 2023Publication date: April 25, 2024Applicant: SQZ Biotechnologies CompanyInventors: Armon R. SHAREI, Howard BERNSTEIN, Scott LOUGHHEAD, Matthew BOOTY, Katarina BLAGOVIC, Kelan HLAVATY, Defne YARAR, Emrah Ilker OZAY, Carolyne Kelly SMITH
-
Publication number: 20230357782Abstract: The present disclosure pertains to methods for delivering a compound into a cell comprising a cell wall, including passing a cell suspension through a constriction, wherein said constriction deforms the cell comprising a cell wall, thereby causing a perturbation of the cell such that the compound enters the cell, wherein said cell suspension is contacted with the compound.Type: ApplicationFiled: March 27, 2023Publication date: November 9, 2023Applicant: SQZ Biotechnologies CompanyInventors: Armon R. SHAREI, Howard BERNSTEIN, Jonathan B. GILBERT
-
Patent number: 11806714Abstract: Isolating or identifying a cell based on a physical property of said cell can include providing a cell suspension; passing said suspension through a microfluidic channel that includes a constriction; passing the cell suspension through the constriction; and, contacting said cell suspension solution with a compound. The constriction can be sized to preferentially deform a relatively larger cell compared to a relatively smaller cell.Type: GrantFiled: October 20, 2020Date of Patent: November 7, 2023Assignee: Massachusetts Institute of TechnologyInventors: Armon R. Sharei, Viktor A. Adalsteinsson, Nahyun Cho, Robert S. Langer, J. Christopher Love, Klavs F. Jensen
-
Publication number: 20230272427Abstract: The present disclosure pertains to methods and devices for delivering a compound into a cell, including passing a cell suspension through a surface containing pores, wherein the pores deform the cell thereby causing a perturbation of the cell such that the compound enters the cell, wherein the cell suspension is contacted with the compound.Type: ApplicationFiled: January 23, 2023Publication date: August 31, 2023Applicant: SQZ Biotechnologies CompanyInventors: Jonathan B. GILBERT, Kirubel FREW, Howard BERNSTEIN, Armon R. SHAREI
-
Publication number: 20230263879Abstract: The present application provides nucleated cells comprising a protein or fragment thereof, methods of manufacturing such nucleated cells comprising the protein or fragment thereof, and methods of using such modified nucleated cells (e.g., immune cells) for stimulating an immune response in a HLA agnostic manner.Type: ApplicationFiled: September 1, 2021Publication date: August 24, 2023Applicant: SQZ Biotechnologies CompanyInventors: Emrah Ilker OZAY, Michael MALONEY, Scott LOUGHHEAD, Howard BERNSTEIN, Katherine SEIDL, Melissa MYINT, Armon R. SHAREI
-
Patent number: 11692168Abstract: The present application provides peripheral blood mononuclear cells comprising an antigen, methods of manufacturing such PBMCs, and methods of using such PBMCs, such as for modulating an immune response in an individual. In some embodiments, the PBMCs are conditioned by incubating the PBMC in the presence of an adjuvant.Type: GrantFiled: February 27, 2020Date of Patent: July 4, 2023Assignee: SQZ Biotechnologies CompanyInventors: Armon R. Sharei, Howard Bernstein, Scott Loughhead, Matthew Booty, Katarina Blagovic, Kelan Hlavaty, Defne Yarar, Emrah Ilker Ozay, Carolyne Kelly Smith
-
Publication number: 20230130686Abstract: A microfluidic system for causing perturbations in a cell membrane, the system including a microfluidic channel defining a lumen and being configured such that a cell suspended in a buffer can pass therethrough, wherein the microfluidic channel includes a cell-deforming constriction, wherein a diameter of the constriction is a function of the diameter of the cell.Type: ApplicationFiled: October 25, 2021Publication date: April 27, 2023Applicant: Massachusetts Institute of TechnologyInventors: Armon R. Sharei, Andrea Adamo, Robert S. Langer, Klavs F. Jensen
-
Publication number: 20230097861Abstract: The present invention provides methods for delivering a transient and/or reversible complex into a cell including passing a cell suspension through a constriction, wherein said constriction deforms the cell, thereby causing a perturbation of the cell such that the complex enters the cell.Type: ApplicationFiled: August 29, 2022Publication date: March 30, 2023Applicant: SQZ Biotechnologies CompanyInventors: Tia DITOMMASO, Howard BERNSTEIN, Armon R. SHAREI, Jonathan B. GILBERT
-
Patent number: 11613759Abstract: The present disclosure pertains to methods for delivering a compound into a cell comprising a cell wall, including passing a cell suspension through a constriction, wherein said constriction deforms the cell comprising a cell wall, thereby causing a perturbation of the cell such that the compound enters the cell, wherein said cell suspension is contacted with the compound.Type: GrantFiled: September 2, 2016Date of Patent: March 28, 2023Assignee: SQZ Biotechnologies CompanyInventors: Armon R. Sharei, Howard Bernstein, Jonathan B. Gilbert
-
Publication number: 20220241392Abstract: The present application provides formulations of modified peripheral blood mononuclear cells (PBMCs), wherein the formulation comprises: PBMCs comprising at least one antigen (e.g., a human papillomavirus (HPV) antigen) and a cryopreservation medium. In some embodiments, the PBMCs are conditioned by incubating the PBMC in the presence of an adjuvant.Type: ApplicationFiled: December 28, 2021Publication date: August 4, 2022Inventors: Howard BERNSTEIN, Scott LOUGHHEAD, Matthew BOOTY, Kelan HLAVATY, Tarek ABDELJAWAD, Maisam DADGAR, Jason MURRAY, David CHIRGWIN, Harry AN, Armon R. SHAREI
-
Publication number: 20220204902Abstract: A microfluidic chip for causing the delivery of a payload to a cell comprises a plurality of constrictions configured to allow a cell suspension to flow through one or more of the plurality of constrictions from a first fluid flow region to a second fluid flow region within the microfluidic chip, wherein a cross-sectional width of each of the plurality of constrictions is less than a diameter of cells in the cell suspension, such that membranes of the cells are perturbed when passing through the constrictions such that a payload is able to pass through the perturbed cell membranes, and wherein a quotient of a cross-sectional area over a cross-sectional perimeter of each of the plurality of constrictions is greater than greater than or equal to 0.5 ?m.Type: ApplicationFiled: December 27, 2021Publication date: June 30, 2022Inventors: Maisam DADGAR, Jacquelyn L. Sikora HANSON, Armon R. SHAREI
-
Publication number: 20220195364Abstract: The current subject matter includes methods, systems, articles, and techniques to deliver material to anucleate cells, such as red blood cells. Using a rapid deformation based microfluidic system, loading of red blood cells with macromolecules of different sizes has been shown. Although delivery to some mammalian cells, such as cancer cell lines and fibroblasts had been previously demonstrated using this technique, those designs were incompatible with RBCs that have dramatically different physical properties. Through the use of smaller constriction sizes, high speeds and different buffers successful delivery to red blood cells can be achieved. By enabling robust delivery to red blood cells in a simple, scalable manner, the current subject matter can be implemented in a diversity of applications that deliver material to study red blood cell diseases and/or use red blood cells as a therapeutic platform. Related apparatus, systems, techniques, and articles are also described.Type: ApplicationFiled: March 8, 2022Publication date: June 23, 2022Applicant: Massachusetts Institute of TechnologyInventors: Armon R. Sharei, Klavs F. Jensen, James Robbins Abshire, Jacquin Clarence Niles
-
Patent number: 11299698Abstract: The current subject matter includes methods, systems, articles, and techniques to deliver material to anucleate cells, such as red blood cells. Using a rapid deformation based microfluidic system, loading of red blood cells with macromolecules of different sizes has been shown. Although delivery to some mammalian cells, such as cancer cell lines and fibroblasts had been previously demonstrated using this technique, those designs were incompatible with RBCs that have dramatically different physical properties. Through the use of smaller constriction sizes, high speeds and different buffers successful delivery to red blood cells can be achieved. By enabling robust delivery to red blood cells in a simple, scalable manner, the current subject matter can be implemented in a diversity of applications that deliver material to study red blood cell diseases and/or use red blood cells as a therapeutic platform. Related apparatus, systems, techniques, and articles are also described.Type: GrantFiled: January 9, 2018Date of Patent: April 12, 2022Assignee: Massachusetts Institute of TechnologyInventors: Armon R. Sharei, Klavs F. Jensen, James Robbins Abshire, Jacquin Clarence Niles
-
Publication number: 20220105166Abstract: The present invention provides methods for stimulating an immune response to an antigen comprising administering to an individual, an anucleate cell-derived vesicle comprising an antigen and/or an adjuvant. In some embodiments, the anucleate cell-derived vesicle comprising the antigen and/or adjuvant is generated by passing a cell suspension containing an input anucleate cell through a constriction, wherein the constriction deforms the input anucleate cell thereby causing a perturbation of the cell to form an anucleate cell-derived vesicle such that an antigen and/or an adjuvant enters the anucleate cell-derived vesicle. In some embodiments, the anucleate cell-derived vesicle comprising the antigen and/or adjuvant is delivered to an individual and the antigen is delivered to and processed in an immunogenic environment to treat a disease, prevent a disease, and/or vaccinate an individual against an antigen.Type: ApplicationFiled: January 24, 2020Publication date: April 7, 2022Applicant: SQZ Biotechnologies CompanyInventors: Armon R. SHAREI, Howard BERNSTEIN, Jonathan B. GILBERT, Finola MOORE, Devin BRIDGEN, Luke CASSEREAU